Xenetic Biosciences (NASDAQ:XBIO) vs. Daré Bioscience (NASDAQ:DARE) Head-To-Head Survey

Daré Bioscience (NASDAQ:DARE) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Profitability

This table compares Daré Bioscience and Xenetic Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daré Bioscience	-191.65%	N/A	-18.98%
Xenetic Biosciences	-161.63%	-49.51%	-43.99%

Earnings and Valuation

This table compares Daré Bioscience and Xenetic Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daré Bioscience	$9,784.00	2,632.21	-$30.16 million	($0.51)	-5.71
Xenetic Biosciences	$2.50 million	1.89	-$4.14 million	($2.57)	-1.19

Xenetic Biosciences has higher revenue and earnings than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Daré Bioscience has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Daré Bioscience and Xenetic Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daré Bioscience	0	1	2	0	2.67
Xenetic Biosciences	0	1	0	0	2.00

Daré Bioscience presently has a consensus price target of $24.00, suggesting a potential upside of 724.74%. Given Daré Bioscience’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Daré Bioscience is more favorable than Xenetic Biosciences.

Institutional & Insider Ownership

6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 4.0% of Daré Bioscience shares are held by company insiders. Comparatively, 14.7% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

About Daré Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.